比较MR引导放疗中前列腺癌的重新定位与再计划策略
本研究回顾性分析19例前列腺癌患者,基于每周MRI比较MRgRT中软组织匹配重新定位与自适应再计划的剂量学差异。自适应计划在治疗期间保持靶区覆盖稳定,但膀胱受量劣于重新定位计划;重新定位计划可维持靶区覆盖且危及器官在临床耐受范围内。
要点
- 自适应再计划保持靶区覆盖稳定,但膀胱剂量劣于重新定位。
- 重新定位计划可维持靶区覆盖,危及器官在临床耐受水平。
- 器官位置和体积显著变化时,自适应再计划更有益。
核心结论
- 基于靶区的重新定位可相对保持靶区覆盖且危及器官在临床耐受水平,自适应再计划未临床改善危及器官剂量但保持靶区剂量恒定,器官位置和体积显著变化时自适应再计划有益。
研究设计与样本
- 回顾性研究,共纳入19例前列腺癌患者,每周采集MRI共5周,在ViewRay系统上以13个共面60Co束生成初始IMRT计划,比较重新定位(软组织匹配)与再计划(自适应计划)两种技术。
主要发现
- 自适应计划在治疗期间显示更好的靶区覆盖,而重新定位计划无显著变化。
- 重新定位与自适应计划间PTV的D98%、D95%、D2%有显著差异(p<0.05),Dmean无显著差异。
- 随治疗进展,所有计划的Dmax和Dmean无显著变化。
- 自适应计划各指标在治疗过程中与初始IMRT保持相同。
- 重新定位与自适应计划间膀胱D15%、D25%、D35%、D50%有显著差异,自适应计划膀胱剂量保护更差;直肠仅D15%和D35%有显著差异(p<0.05),自适应计划保护更好。
关键数值与推荐
- PTV参数:重新定位与自适应计划间D98%、D95%、D2%有显著差异(p<0.05),Dmean无显著差异。
- 膀胱参数:重新定位与自适应计划间D15%、D25%、D35%、D50%有显著差异。
- 直肠参数:重新定位与自适应计划间D15%和D35%有显著差异(p<0.05)。
临床怎么用
- 基于靶区的重新定位可在治疗过程中相对保持靶区覆盖并使危及器官处于临床耐受水平。
- 自适应再计划未临床改善危及器官剂量,但保持靶区剂量恒定。
- 当器官位置和体积变化显著时,自适应再计划有益。
局限性
- 回顾性研究,样本量19例。
- 仅使用每周MRI扫描观察解剖变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compared adaptive replanning and repositioning corrections based on soft-tissue matching for prostate cancer by using the magnetic resonance-guided radiation therapy (MRgRT) system. METHODS: A total of 19 patients with prostate cancer were selected retrospectively. Weekly magnetic resonance image (MRI) scans were acquired for 5 weeks for each patient to observe the anatomic changes during the treatment course. Initial intensity-modulated radiation therapy (IMRT) plans (iIMRT) were generated for each patient with 13 coplanar 60Co beams on a ViewRay™ system. Two techniques were applied: patient repositioning and replanning. For patient repositioning, one plan was created: soft-tissue (prostate) matching (Soft). The dose distribution was calculated for each MRI with the beam delivery parameters from the initial IMRT plan. The replanning technique was used to generate the Adaptive plan, which was the reoptimized plan for the weekly MRI. The dose-volumetric parameters of the planning target volume (PTV), bladder, and rectum were calculated for all plans. During the treatment course, the PTV, bladder, and rectum were evaluated for changes in volume and the effect on dosimetric parameters. The differences between the dose-volumetric parameters of the plans were examined through the Wilcoxon test. The initial plan was used as a baseline to compare the differences. RESULTS: The Adaptive plan showed better target coverage during the treatment period, but the change was not significant in the Soft plan. There were significant differences in D98%, D95%, and D2% in PTV between the Soft and Adaptive plans (p < 0.05) except for Dmean. There was no significant change in Dmax and Dmean as the treatment progressed with all plans. All indices for the Adaptive plan stayed the same compared to those of iIMRT during the treatment course. There were significant differences in D15%, D25%, D35%, and D50% in the bladder between the Soft and Adaptive plans. The Adaptive plan showed the worse dose sparing than the Soft plan for the bladder according to each dosimetric index. In contrast to the bladder, the Adaptive plan achieved better sparing than the Soft plan during the treatment course. The significant differences were only observed in D15% and D35% between the Soft and Adaptive plans (p < 0.05). CONCLUSIONS: Patient repositioning based on the target volume (Soft plan) can relatively retain the target coverage for patients and the OARs remain at a clinically tolerance level during the treatment course. The Adaptive plan did not clinically improve for the dose delivered to OARs, it kept the dose delivered to the target volume constant. However, the Adaptive plan is beneficial when the organ positions and volumes change considerable during treatment.
引用
- Kim JI, Park JM, Choi CH, et al. Retrospective study comparing MR-guided radiation therapy (MRgRT) setup strategies for prostate treatment: repositioning vs. replanning. Radiat Oncol. 2019. PMID: 31387593. doi:10.1186/s13014-019-1349-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。